This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Multiple Indications | Pradaxa® (dabigatran etexilate) Skip to main content

*Findings were consistent with results of the pivotal RE‑LY® Trial, with the exception of the MI finding. An increased risk of MI was observed for PRADAXA compared to warfarin in RE-LY®.
Composite of confirmed VTE (proximal or distal DVT on venogram, confirmed symptomatic DVT, or confirmed PE) and all-cause death.

  • References:
  • 1. Data on File. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
  • 3. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272‑1274.
  • 4. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157‑164.
  • 5. Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114(6):1290-1298.
  • 6. Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015;114(6):1277-1289.
  • 7. Bridges FM, Spence M, Niu F, et al. Poster: Comparative effectiveness and safety of warfarin and dabigatran for the management of atrial fibrillation in an integrated healthcare delivery system. Month 2016.